CO6300939A2 - Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada - Google Patents
Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionadaInfo
- Publication number
- CO6300939A2 CO6300939A2 CO10116702A CO10116702A CO6300939A2 CO 6300939 A2 CO6300939 A2 CO 6300939A2 CO 10116702 A CO10116702 A CO 10116702A CO 10116702 A CO10116702 A CO 10116702A CO 6300939 A2 CO6300939 A2 CO 6300939A2
- Authority
- CO
- Colombia
- Prior art keywords
- referring
- related application
- new compounds
- erk inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3040708P | 2008-02-21 | 2008-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6300939A2 true CO6300939A2 (es) | 2011-07-21 |
Family
ID=40601237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10116702A CO6300939A2 (es) | 2008-02-21 | 2010-09-21 | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada |
Country Status (23)
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
KR20080103996A (ko) | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Erk 억제제로서 피롤리딘 유도체 |
US8586543B2 (en) | 2008-08-19 | 2013-11-19 | Merck Sharp & Dohme Corp. | IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
WO2011002887A1 (en) | 2009-07-02 | 2011-01-06 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS |
EP2483263B1 (en) | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclic compounds that are erk inhibitors |
WO2011163330A1 (en) * | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
EP2615916B1 (en) * | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
EP2630133A1 (de) | 2010-10-22 | 2013-08-28 | Bayer Intellectual Property GmbH | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
WO2012068148A1 (en) * | 2010-11-16 | 2012-05-24 | Medimmune, Llc | Regimens for treatments using anti-igf antibodies |
US9000209B2 (en) | 2011-07-22 | 2015-04-07 | Iowa State University Research Foundation, Inc. | Method of regioselective synthesis of substituted benzoates |
ES2857649T3 (es) | 2012-03-01 | 2021-09-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
CA2872110C (en) | 2012-07-18 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
RU2660429C2 (ru) * | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
WO2014052566A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
CA3005118A1 (en) * | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
US8871966B2 (en) | 2013-03-15 | 2014-10-28 | Iowa State University Research Foundation, Inc. | Regiospecific synthesis of terephthalates |
EA032196B1 (ru) | 2013-10-03 | 2019-04-30 | Кура Онколоджи, Инк. | Ингибиторы erk и способы применения |
US10428387B2 (en) | 2014-05-16 | 2019-10-01 | University Of Massachusetts | Treating chronic myelogenous leukemia (CML) |
WO2016025639A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a chemotherapeutic agent and related methods |
WO2016095089A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
WO2016095088A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
AU2015362844B2 (en) | 2014-12-18 | 2019-10-24 | Merck Sharp & Dohme Corp. | (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations |
BR112017012558A2 (pt) | 2014-12-19 | 2018-01-02 | Merck Sharp & Dohme | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas |
AU2016242940B2 (en) * | 2015-04-03 | 2020-11-05 | Recurium Ip Holdings, Llc | Spirocyclic compounds |
US20180250232A1 (en) * | 2015-09-03 | 2018-09-06 | Merck Sharp & Dohme Corp. | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations |
CN106432182B (zh) * | 2016-09-06 | 2019-04-30 | 铜仁学院 | 特地唑胺中间体的合成方法 |
CN109020789B (zh) * | 2017-06-12 | 2021-08-13 | 浙江医药股份有限公司新昌制药厂 | 一种制备2-甲氧基丙烯的方法 |
WO2021067266A1 (en) * | 2019-10-01 | 2021-04-08 | Recurium Ip Holdings, Llc | Pyrrolidinyl-based compounds |
EP4041393A1 (en) | 2019-10-09 | 2022-08-17 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
GB2323845A (en) | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
DE69841434D1 (de) | 1997-07-18 | 2010-02-25 | Novo Nordisk Healthcare Ag | VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
SK14082001A3 (sk) | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
EP1318997B1 (en) | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022610A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
EP1353905B1 (en) * | 2000-11-20 | 2007-01-10 | Scios Inc. | Piperidine/piperazine-type inhibitors of p38 kinase |
IL156368A0 (en) | 2000-12-21 | 2004-01-04 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
CA2440842A1 (en) * | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Novel 1h-indazole compounds |
US6962936B2 (en) | 2001-04-27 | 2005-11-08 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
AU2002305260A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
WO2003011854A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
DE60226154T2 (de) | 2001-08-03 | 2009-05-20 | Vertex Pharmaceuticals Inc., Cambridge | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
WO2003035626A2 (en) | 2001-10-23 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Azole derivatives and pharmaceutical compositions containing them |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
WO2003099212A2 (en) | 2002-05-24 | 2003-12-04 | The University Of Utah Research Foundation | Mitogen activated protein kinase inhibitor compositions for lymphoma therapy |
AU2003241925A1 (en) * | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
AR041291A1 (es) | 2002-09-19 | 2005-05-11 | Schering Corp | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina |
EP1606284B1 (en) | 2003-03-13 | 2009-12-02 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
EP1791831A4 (en) * | 2003-11-19 | 2009-07-08 | Signal Pharm Llc | METHOD FOR THE TREATMENT OF DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES |
WO2005063258A1 (en) | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
JP2007530595A (ja) | 2004-03-26 | 2007-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erk2のピリジンインヒビターおよびそれらの使用 |
JP2007532615A (ja) | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
JP4993604B2 (ja) | 2004-05-14 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリルピリミジンerkプロテインキナーゼインヒビターのプロドラッグ |
ES2897422T3 (es) | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
EP1833820A1 (en) | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinase and uses therof |
CN100377868C (zh) * | 2005-03-24 | 2008-04-02 | 中国科学院物理研究所 | 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途 |
WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
US8217042B2 (en) * | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
RS51981B (en) * | 2005-12-13 | 2012-02-29 | Schering Corporation | POLYCYCLIC INDASOL DERIVATIVES WHICH ARE ERK INHIBITORS |
KR20080103996A (ko) * | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Erk 억제제로서 피롤리딘 유도체 |
EP2260869A3 (en) * | 2006-04-20 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical product |
US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
BRPI0713119A2 (pt) * | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
US7671832B2 (en) * | 2006-07-10 | 2010-03-02 | Philips Lumileds Lighting Company, Llc | Multi-colored LED backlight with color-compensated clusters near edge |
CA3001152A1 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
JP2010529122A (ja) * | 2007-06-05 | 2010-08-26 | シェーリング コーポレイション | 多環式インダゾール誘導体および癌の治療のためのerk阻害剤としてのそれらの使用 |
JP5451602B2 (ja) | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | キナーゼ阻害薬としての5−ヘテロアリール置換インダゾール類 |
CA2691417A1 (en) | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
EP2483263B1 (en) | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclic compounds that are erk inhibitors |
-
2009
- 2009-02-19 WO PCT/US2009/034447 patent/WO2009105500A1/en active Application Filing
- 2009-02-19 CA CA2714479A patent/CA2714479A1/en not_active Abandoned
- 2009-02-19 NZ NZ587504A patent/NZ587504A/xx not_active IP Right Cessation
- 2009-02-19 SG SG2013013206A patent/SG188179A1/en unknown
- 2009-02-19 US US12/918,099 patent/US8716483B2/en active Active
- 2009-02-19 MX MX2010009268A patent/MX2010009268A/es active IP Right Grant
- 2009-02-19 RU RU2010138635/04A patent/RU2525389C2/ru not_active IP Right Cessation
- 2009-02-19 BR BRPI0908120A patent/BRPI0908120A8/pt not_active IP Right Cessation
- 2009-02-19 KR KR1020107020896A patent/KR20100117123A/ko not_active Application Discontinuation
- 2009-02-19 MY MYPI20103904 patent/MY152271A/en unknown
- 2009-02-19 JP JP2010547732A patent/JP5276676B2/ja not_active Expired - Fee Related
- 2009-02-19 EP EP09712601.5A patent/EP2260031B1/en active Active
- 2009-02-19 AU AU2009215534A patent/AU2009215534B8/en not_active Ceased
- 2009-02-19 ES ES09712601.5T patent/ES2556353T3/es active Active
- 2009-02-19 CN CN200980113870.7A patent/CN102015693B/zh not_active Expired - Fee Related
- 2009-02-20 PE PE2009000250A patent/PE20091491A1/es active IP Right Grant
- 2009-02-20 AR ARP090100604A patent/AR070460A1/es active IP Right Grant
- 2009-02-20 CL CL2009000394A patent/CL2009000394A1/es unknown
- 2009-02-20 TW TW098105537A patent/TWI398441B/zh not_active IP Right Cessation
-
2010
- 2010-08-10 IL IL207530A patent/IL207530A/en active IP Right Grant
- 2010-08-18 ZA ZA2010/05909A patent/ZA201005909B/en unknown
- 2010-08-20 EC EC2010010415A patent/ECSP10010415A/es unknown
- 2010-09-21 CO CO10116702A patent/CO6300939A2/es active IP Right Grant
-
2014
- 2014-01-17 ZA ZA2014/00396A patent/ZA201400396B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6300939A2 (es) | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada | |
ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
CR20120414A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
UY31774A (es) | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos | |
UY33921A (es) | Oxazinopteridinas y oxazinoptiridinonas n-sustituidas | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
CR20150045A (es) | Inhibidores de hepatitis c | |
CU20100238A7 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato | |
CR20140544A (es) | Compuestos para inhibir la progresión mitotica | |
CU20110204A7 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
UY33226A (es) | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 | |
CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
SV2009003389A (es) | Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer | |
ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
ECSP089019A (es) | Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa | |
CL2023002486A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
UY29804A1 (es) | Quinolinas de alquilnitrilo | |
DOP2011000053A (es) | Agentes antifungicos | |
CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
ECSP13012372A (es) | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused | ||
FG | Application granted |